AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

NCT06464068 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
66
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica